BR112016003201A2 - inibidores de grp94 seletivos e usos dos mesmos - Google Patents

inibidores de grp94 seletivos e usos dos mesmos

Info

Publication number
BR112016003201A2
BR112016003201A2 BR112016003201A BR112016003201A BR112016003201A2 BR 112016003201 A2 BR112016003201 A2 BR 112016003201A2 BR 112016003201 A BR112016003201 A BR 112016003201A BR 112016003201 A BR112016003201 A BR 112016003201A BR 112016003201 A2 BR112016003201 A2 BR 112016003201A2
Authority
BR
Brazil
Prior art keywords
grp94 inhibitors
selective grp94
compounds
effective amount
selective
Prior art date
Application number
BR112016003201A
Other languages
English (en)
Inventor
Yang Chenghua
Chiosis Gabriela
J Patel Hardik
Patel Pallav
Yan Pengrong
O Ochiana Stefan
Taldone Tony
Sun Weilin
Original Assignee
Memorial Sloan Kettering Cancer Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Memorial Sloan Kettering Cancer Center filed Critical Memorial Sloan Kettering Cancer Center
Publication of BR112016003201A2 publication Critical patent/BR112016003201A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B35/00—ICT specially adapted for in silico combinatorial libraries of nucleic acids, proteins or peptides
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16C—COMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE
    • G16C20/00—Chemoinformatics, i.e. ICT specially adapted for the handling of physicochemical or structural data of chemical particles, elements, compounds or mixtures
    • G16C20/60—In silico combinatorial chemistry
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16C—COMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE
    • G16C20/00—Chemoinformatics, i.e. ICT specially adapted for the handling of physicochemical or structural data of chemical particles, elements, compounds or mixtures
    • G16C20/60—In silico combinatorial chemistry
    • G16C20/64—Screening of libraries

Abstract

a presente invenção refere-se a novos inibidores de grp94 seletivos, composições compreendendo uma quantidade eficaz de tais compostos e métodos para tratar ou prevenir uma condição, tal como câncer, compreendendo administração a um animal com necessidade do mesmo de uma quantidade eficaz de tais compostos.
BR112016003201A 2013-08-16 2014-08-15 inibidores de grp94 seletivos e usos dos mesmos BR112016003201A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361866932P 2013-08-16 2013-08-16
PCT/US2014/051332 WO2015023976A2 (en) 2013-08-16 2014-08-15 Selective grp94 inhibitors and uses thereof

Publications (1)

Publication Number Publication Date
BR112016003201A2 true BR112016003201A2 (pt) 2017-11-21

Family

ID=52468819

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016003201A BR112016003201A2 (pt) 2013-08-16 2014-08-15 inibidores de grp94 seletivos e usos dos mesmos

Country Status (17)

Country Link
US (3) US10421758B2 (pt)
EP (1) EP3033338A4 (pt)
JP (2) JP6539275B2 (pt)
KR (1) KR102319582B1 (pt)
CN (1) CN105899503B (pt)
AU (2) AU2014306417C1 (pt)
BR (1) BR112016003201A2 (pt)
CA (1) CA2921571C (pt)
EA (1) EA201690406A1 (pt)
HK (1) HK1226063A1 (pt)
IL (2) IL244251B (pt)
MX (1) MX370664B (pt)
PH (1) PH12016500511A1 (pt)
SG (2) SG11201601542SA (pt)
TW (1) TWI711618B (pt)
WO (1) WO2015023976A2 (pt)
ZA (1) ZA201601794B (pt)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9403828B2 (en) 2005-02-01 2016-08-02 Sloan-Kettering Institute For Cancer Research Small-molecule Hsp90 inhibitors
US7834181B2 (en) 2005-02-01 2010-11-16 Slaon-Kettering Institute For Cancer Research Small-molecule Hsp90 inhibitors
CA2656202C (en) 2006-06-30 2018-01-16 Sloan-Kettering Institute For Cancer Research Treatment of neurodegenerative diseases through inhibition of hsp90
BR112012008019A2 (pt) 2009-10-07 2016-03-01 Sloan Kettering Inst Cancer derivados de purina úteis como inibidores de hsp90
ES2647889T3 (es) 2011-04-05 2017-12-27 Sloan-Kettering Institute For Cancer Research Inhibidores de la Hsp90
MX360390B (es) 2011-04-05 2018-10-31 Sloan Kettering Inst Cancer Res Inhibidores de la proteina 90 de choque termico (hsp90).
US9409139B2 (en) * 2013-08-05 2016-08-09 Twist Bioscience Corporation De novo synthesized gene libraries
JP6539275B2 (ja) * 2013-08-16 2019-07-03 メモリアル スローン ケタリング キャンサー センター 選択的ｇｒｐ９４阻害剤およびその使用
WO2015138039A1 (en) * 2013-12-23 2015-09-17 Memorial Sloan-Kettering Cancer Center Methods and reagents for radiolabeling
AU2015317632B2 (en) 2014-09-17 2022-01-13 Memorial Sloan Kettering Cancer Center Hsp90-targeted inflammation and infection imaging and therapy
TW201722422A (zh) 2015-10-05 2017-07-01 美國紀念斯隆-凱特琳癌症中心 用於治療癌症之合理組合療法
CN108503643B (zh) * 2017-02-28 2020-09-15 泉州易初生物医药科技有限公司 蛋白酶抑制剂的制备方法
EP3595636A4 (en) * 2017-03-16 2021-01-13 Children's Medical Center Corporation GENETICALLY PRODUCED LIPOSOMES AS TARGETED THERAPEUTICS AGAINST CANCER
US20200338084A1 (en) * 2018-01-02 2020-10-29 Sanford Burnham Prebys Medical Discovery Institute Inhibitors of low molecular weight protein tyrosine phosphatase (lmptp) and uses thereof
US11774451B2 (en) * 2019-11-21 2023-10-03 The Board Of Trustees Of The Leland Stanford Junior University Molecular vibrational spectroscopic markers for detection of cancer
US20230220056A1 (en) * 2020-06-09 2023-07-13 Kookmin University Industry Academy Cooperation Foundation Antibody specifically binding to grp94 or antigen-binding fragment thereof, and uses thereof
KR20230000050A (ko) 2021-06-24 2023-01-02 최현지 페이크 마스크
CN113663078B (zh) * 2021-06-28 2023-05-16 四川大学 Grp94抑制剂在制备治疗EGFR驱动的癌症的药物中的用途
KR20240012846A (ko) 2022-07-21 2024-01-30 성균관대학교산학협력단 신규한 hdac6 선택적 억제제 및 이의 용도
CN115717144A (zh) * 2022-08-25 2023-02-28 南通市肿瘤医院 抑制hsp90b1表达的小干扰rna及其在膀胱癌衰老中的应用

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE195735T1 (de) 1993-07-15 2000-09-15 Minnesota Mining & Mfg Imidazo (4,5-c)pyridin-4-amine
JP2005519848A (ja) * 2000-11-02 2005-07-07 スローン−ケッタリング・インスティテュート・フォー・キャンサー・リサーチ Ｈｓｐ９０に結合するための小分子組成物
EP1440072A4 (en) 2001-10-30 2005-02-02 Conforma Therapeutic Corp PURINE ANALOGS HAVING HSP90 INHIBITORY ACTIVITY
US20070129334A1 (en) * 2001-10-30 2007-06-07 Conforma Therapeutics Corporation Orally Active Purine-Based Inhibitors of Heat Shock Protein 90
US7553979B2 (en) 2001-11-09 2009-06-30 Conforma Therapeutics Corporation HSP90-inhibiting zearalanol compounds and methods of producing and using same
CN101906106A (zh) 2003-09-18 2010-12-08 康福玛医药公司 作为hsp90-抑制剂的新的杂环化合物
US7834181B2 (en) 2005-02-01 2010-11-16 Slaon-Kettering Institute For Cancer Research Small-molecule Hsp90 inhibitors
US9403828B2 (en) 2005-02-01 2016-08-02 Sloan-Kettering Institute For Cancer Research Small-molecule Hsp90 inhibitors
JP2009521446A (ja) 2005-12-22 2009-06-04 コンフォーマ・セラピューティクス・コーポレイション 熱ショックタンパク質９０の経口活性なプリンベースの阻害剤
AU2007249194B2 (en) * 2006-05-12 2012-11-22 Myrexis, Inc. Therapeutic compounds and their use in cancer
CA2656202C (en) 2006-06-30 2018-01-16 Sloan-Kettering Institute For Cancer Research Treatment of neurodegenerative diseases through inhibition of hsp90
EP2069794A1 (en) * 2006-10-03 2009-06-17 University of Southern California Grp78 as a predictor of responsiveness to therapeutic agents
AU2008229216B2 (en) 2007-03-20 2013-03-21 Curis, Inc. Fused amino pyridine as HSP90 inhibitors
JP2011503206A (ja) 2007-11-14 2011-01-27 ミレクシス， インコーポレイテッド 疾患および障害の治療における治療化合物およびその使用方法
WO2010042500A2 (en) * 2008-10-06 2010-04-15 Emory University Heat shock protein 90 inhibitors, methods of preparing same, and methods for their use
BR112012008019A2 (pt) 2009-10-07 2016-03-01 Sloan Kettering Inst Cancer derivados de purina úteis como inibidores de hsp90
MX360390B (es) 2011-04-05 2018-10-31 Sloan Kettering Inst Cancer Res Inhibidores de la proteina 90 de choque termico (hsp90).
ES2647889T3 (es) 2011-04-05 2017-12-27 Sloan-Kettering Institute For Cancer Research Inhibidores de la Hsp90
WO2012139010A1 (en) 2011-04-08 2012-10-11 University Of Kansas Grp94 inhibitors
WO2012166617A2 (en) 2011-05-27 2012-12-06 Cytocure Llc Methods, compositions, and kits for the treatment of cancer
CA2841173C (en) * 2011-07-08 2022-06-21 Sloan-Kettering Institute For Cancer Research Uses of labeled hsp90 inhibitors
JP6539275B2 (ja) 2013-08-16 2019-07-03 メモリアル スローン ケタリング キャンサー センター 選択的ｇｒｐ９４阻害剤およびその使用

Also Published As

Publication number Publication date
JP6539275B2 (ja) 2019-07-03
EP3033338A2 (en) 2016-06-22
US11267816B2 (en) 2022-03-08
CN105899503A (zh) 2016-08-24
IL267681B (en) 2022-11-01
PH12016500511A1 (en) 2016-06-13
EP3033338A4 (en) 2017-06-14
IL244251A0 (en) 2016-04-21
SG10201801281QA (en) 2018-04-27
CA2921571C (en) 2022-04-05
MX370664B (es) 2019-12-19
US20160194328A1 (en) 2016-07-07
CN105899503B (zh) 2020-08-18
US10421758B2 (en) 2019-09-24
JP2016533384A (ja) 2016-10-27
AU2019202669B2 (en) 2020-12-03
IL244251B (en) 2019-07-31
JP6848009B2 (ja) 2021-03-24
AU2014306417A1 (en) 2016-03-17
SG11201601542SA (en) 2016-04-28
HK1226063A1 (zh) 2017-09-22
KR102319582B1 (ko) 2021-11-04
IL267681A (en) 2019-08-29
JP2019178147A (ja) 2019-10-17
WO2015023976A2 (en) 2015-02-19
TWI711618B (zh) 2020-12-01
TW201516047A (zh) 2015-05-01
AU2014306417C1 (en) 2019-07-25
CA2921571A1 (en) 2015-02-19
AU2019202669A1 (en) 2019-05-09
US20200102312A1 (en) 2020-04-02
AU2014306417B2 (en) 2019-01-17
KR20160043534A (ko) 2016-04-21
EA201690406A1 (ru) 2016-08-31
IL267681B2 (en) 2023-03-01
US20230123747A1 (en) 2023-04-20
WO2015023976A3 (en) 2015-04-23
MX2016002077A (es) 2016-07-21
ZA201601794B (en) 2019-09-25

Similar Documents

Publication Publication Date Title
BR112016003201A2 (pt) inibidores de grp94 seletivos e usos dos mesmos
NI201600071A (es) Compuestos de inhibidor de autotaxina
MX2018008052A (es) Inhibidores de desmetilasa especifica de lisina 1 (lsd1).
BR112017000301A2 (pt) tratamento de leucemia com inibidores de histona desacetilase
BR112016014410A2 (pt) terapia de combinação com vacina de neoantígeno
MX371108B (es) Pirimidopirimidinonas utiles como iniciadores de wee-1 cinasa.
BR112016018604A2 (pt) Benzimidazol-2-aminas como inibidores de midh1
EA201690753A1 (ru) Комбинации ингибиторов гистондеацетилазы и иммуномодулирующих лекарственных средств
MX2016003486A (es) Inhibidores de glucosilceramida sintasa para el tratamiento de enfermedades.
BR112015015891A8 (pt) Composição farmacêutica de solução sólida, e, uso de uma composição farmacêutica
DOP2016000253A (es) Nuevos compuestos
ECSP16008797A (es) Derivados de heterobicicloaril como inhibidores rorc2 y métodos de uso de los mismos
BR112018003827A2 (pt) composto, composição farmacêutica, combinação, uso de um composto, e, método para tratamento de uma doença ou condição.
BR112017003433A2 (pt) inibidores espirocíclicos de catepsina c
NI201600070A (es) Inhibidores tetracíclicos de autotaxina
MX2019013808A (es) Compuestos desestabilizadores de microtubulina para usarse en el tratamiento del cancer.
BR112015032763A2 (pt) cd33 solúvel para tratar síndromes mielodisplásicas (mds)
BR112013010136A2 (pt) vacina, composição terapêutica e métodos para o tratamento ou inibição de gliblastoma
BR112017018198A2 (pt) inibição da atividade de olig2
BR112016022749A2 (pt) compostos de azole substituído por amido como inibidores de tnks1 e/ou tnks2
ZA201901367B (en) Inhibition of olig2 activity
DOP2016000251A (es) Inhibidores de las vías de señalización de wnt
EA201500737A1 (ru) Пиразолилкарбоксамиды ii в качестве ингибиторов crac каналов
MX2016004094A (es) Composicion farmaceutica que comprende capecitabina y ciclofosfamida.
PH12020500472A1 (en) Autotaxin inhibitor compounds

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2595 DE 29-09-2020 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.